Targeted Therapy Triplet Shows Promise in R/R Richter’s Transformation and De Novo DLBCL
April 21st 2021Anthony Mato, MD, MSCE, discusses the use of a triplet combination of the novel Bruton tyrosine kinase inhibitor DTRMWXHS-12, the mTOR inhibitor, everolimus, and the IMiD pomalidomide for the treatment of relapsed/refractory Richter’s transformation and de novo diffuse large B-cell lymphoma.
Watch
Phase 3 Study Supports Pembrolizumab in Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma
April 14th 2021The interim analysis from the phase 3 KEYNOTE-204 study suggests pembrolizumab should be considered the preferred treatment option for patients with relapsed or refractory classical Hodgkin lymphoma over brentuximab vedotin.
Read More
CAR T-Cell Therapy Shows Consistent Safety and Pharmacokinetics in NHL
April 12th 2021Scott R. Solomon, MD, discusses the adverse events and pharmacokinetics of lisocabtagene maraleucel in 12 patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who had previously received anti-CD19 therapy.
Watch
Copanlisib Plus Rituximab Extends Progression-Free Survival in Indolent NHL
April 10th 2021Primary results from the phase 3 CHRONOS-3 study revealed a survival benefit with the combination of copanlisib in combination with rituximab over rituximab plus placebo in patients with relapsed indolent non-Hodgkin lymphoma.
Read More
Novel Combinations Excite the R/R Hodgkin Lymphoma Treatment Landscape
April 8th 2021While the treatment of relapsed or refractory Hodgkin lymphoma has seen novel approaches in recent years improving outcomes for many patients, high-risk patients develop progressive disease and have limited treatment options.
Read More
Tuscano Reviews Treatment and Toxicity Management for a Patient With Classic Hodgkin Lymphoma
April 5th 2021Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.
Read More
Axi-cel Shows Better Outcomes When Given After Corticosteroids in R/R LBCL
March 24th 2021Administering corticosteroids prior to chimeric antigen receptor T-cell therapy with axicabtagene ciloleucel in adult patients with relapsed or refractory large B-cell lymphoma may positively impact the benefit/risk profile of axi-cel treatment.
Read More
FDA Approves Axi-Cel for Relapsed/Refractory Follicular Lymphoma in Third-Line or Beyond
March 6th 2021The FDA has granted an accelerated approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
Read More
Brentuximab Vedotin Plus Chemotherapy Works as a Primary Option for Hodgkin Lymphoma
March 5th 2021Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.
Read More
Promising 5-Year Outcomes Shown With CAR T-Cell Therapy in R/R B-Cell Lymphoma
February 24th 2021For the treatment of relapsed or refractory aggressive B-cell lymphomas, chimeric antigen receptor–modified T-cell therapy is becoming more widely used. Still, little is known about outcomes for patients who receive CAR-modified T-cell therapy beyond 2 years.
Read More
Axi-Cel Shows Activity in Relapsed/Refractory DLBCL Regardless of Chemo Sensitivity
February 22nd 2021Data from patients with relapsed/refractory diffuse large B-cell lymphoma treated with axicabtagene ciloleucel showed that post-chimeric antigen receptor T outcomes may not correlate with responsiveness observed with treatment received immediately prior.
Read More
Limited Following of Best Practices for CLL Observed in the Real-World Setting
February 20th 2021Anthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic biomarker testing, treatment patterns and treatment dosing in a pool of 1461 patients with either chronic lymphocytic leukemia.
Watch
Off-the-Shelf NK Immunotherapy Is Safe and Promising in B-Cell NHL With Chemotherapy and Transplant
February 16th 2021Early antitumor activity was seen with cord blood–derived natural killer immunotherapy in combination with high-dose chemotherapy and autologous stem cell transplant in patients with B-cell non-Hodgkin lymphoma, according to early results from a phase 2 trial.
Read More
FDA Approves Liso-Cel CAR T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma
February 5th 2021The FDA has granted approval to lisocabtagene maraleucel a CD19-targeting chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who have received at least 2 prior lines of systemic therapy.
Read More
FDA Grants Accelerated Approval to Umbralisib in Relapsed/Refractory MZL and FL
February 5th 2021The FDA has granted accelerated approval to umbralisib for the treatment of patients with relapsed or refractory marginal zone lymphoma who have received at least 1 prior regimen with anti-CD20 therapy, and for patients with follicular lymphoma who have received at least 2 prior systemic therapies.
Read More
Novel Prognostic and Stratification Index Determined Survival Outcomes for Burkitt Lymphoma
February 5th 2021A collaborative effort between Rutgers Cancer Institute of New Jersey and RWJBarnabas Health has led to the discovery and validation of the novel Burkitt Lymphoma International Prognostic Index, a model for prognostication of patients with Burkitt lymphoma.
Read More